280754-15-6Relevant academic research and scientific papers
2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site
Bestgen, Beno?t,Krimm, Isabelle,Kufareva, Irina,Kamal, Ahmed Ashraf Moustafa,Seetoh, Wei-Guang,Abell, Chris,Hartmann, Rolf W.,Abagyan, Ruben,Cochet, Claude,Le Borgne, Marc,Engel, Matthias,Lomberget, Thierry
, p. 1803 - 1816 (2019/03/07)
CK2 is a ubiquitous Ser/Thr protein kinase involved in the control of various signaling pathways and is known to be constitutively active. In the present study, we identified aryl 2-aminothiazoles as a novel class of CK2 inhibitors, which displayed a non-ATP-competitive mode of action and stabilized an inactive conformation of CK2 in solution. Enzyme kinetics studies, STD NMR, circular dichroism spectroscopy, and native mass spectrometry experiments demonstrated that the compounds bind in an allosteric pocket outside the ATP-binding site. Our data, combined with molecular docking studies, strongly suggested that this new binding site was located at the interface between the αC helix and the flexible glycine-rich loop. A first hit optimization led to compound 7, exhibiting an IC50 of 3.4 μM against purified CK2α in combination with a favorable selectivity profile. Thus, we identified a novel class of CK2 inhibitors targeting an allosteric pocket, offering great potential for further optimization into anticancer drugs.
Synthesis of 5-arylated N-arylthiazole-2-amines as potential skeletal muscle cell differentiation promoters
Schnürch, Michael,Waldner, Birgit,Hilber, Karlheinz,Mihovilovic, Marko D.
experimental part, p. 2149 - 2154 (2011/04/24)
A series of N-arylthiazole-2-amines was prepared and their biological activity for the promotion of skeletal muscle cell differentiation was investigated, a process of significant importance in muscle regeneration. A versatile new synthetic route towards
IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS
-
Page/Page column 156, (2009/01/24)
A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
